IJBPAS, December, 2026, 15(12): 5805-5819

ISSN: 2277–4998

International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS)

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

ARTIFICIAL INTELLIGENCE A REVOLUTIONARY HEALTHCARE TECHNOLOGY IN PHARMACEUTICAL SCIENCES

DEOSARKAR A[1], KAMBLE P[1], UPLANCHIWAR V[1], HIRADEVE S[1], MANE N[1], SURUSE P[1], DEVHARE L[1] AND MAHAJAN R[*2]

1: Nagpur College of Pharmacy, Wanadongri, Hingna Road, Nagpur 441110, Maharashtra, India; Affiliated to Dr. Babasaheb Ambedkar technological University, Raigad, Lonere, Maharashtra, India

2: Taywade College of Pharmacy, Rashtrasant Tukadoji Maharaj Nagpur University, Koradi, Nagpur, Maharashtra, India-441111

***Corresponding Author: Renuka Mahajan: E Mail: mahajan.renuka@gmail.com**

Received 25th May 2026; Revised 20th July 2026; Accepted 1st Sept. 2026; Available online 1st Dec. 2026

https://doi.org/10.31032/IJBPAS/2026/15.12.10649

ABSTRACT

Persistent development of IT tools led invention of AI which is helpful in areas such as drug discovery, target identification, protein structure prediction, virtual screening, hit identification. AI is helping pharmaceutical sciences in designing clinical trials, biomarker analysis, pharmacokinetic, pharmacodynamic models, ADMET prediction, drug repursuing, digital twins production, pharmacovigilance. Present review aims to comprehensively evaluate AI applications across key domains of pharmaceutical sciences including molecular design, clinical trial optimization, pharmacokinetics/pharmacodynamics modelling, pharmacovigilance, precision medicine, pharmaceutical manufacturing, drug delivery systems, and regulatory science. The search engines such as science direct, pubmed, google, Elsevier were used for present review. This completion of data is meant for availability of novel AI techniques/methods to researchers in pharmaceutical production, data management, new drug analysis. Important AI platforms such as AlphaFold2/3, REINVENT, AtomNet, BioBERT and DeepChem have achieved major breakthroughs in protein structure prediction, virtual screening and molecular generation. AI-enabled systems further support adaptive clinical trials, biomarker discovery, adverse drug reactions monitoring, and intelligent manufacturing

processes. However, issues around data quality, model transparency, regulatory validation, privacy and ethical concerns remain an important limitation for wider implementation. Further revolutions in pharmaceutical research and healthcare are expected from developments such as explainable AI, federated learning, AI-powered biologics discovery, and quantum-AI integration. The review reported that AI technologies such as machine learning, deep learning, natural language processing and graph neural networks have achieved significant improvements in different stages of pharmaceutical development. AI tools such as AlphaFold2/3, AtomNet, REINVENT and BioBERT improved molecular design, patient recruitment, PK/PD modelling, toxicity prediction.

Keywords: Artificial Intelligence, Drug discovery and design, Drug delivery, AlphaFold

1. INTRODUCTION

The Pharmaceutical sciences is the life-saving field because of ongoing innovation and adoption of new technologies. We need to adopt pharmaceutical innovations to reduce failure in drug development **[1]**. Drug discovery can averagely cost $ 2.5 billion. This shows higher cost requirement which can be reduced by using the AI **[2]**. John J Hopfield and Goffrey E Hinton were awarded by Nobel Prize in 2024 for innovative discoveries in machine learning [ML] and artificial neural network. Artificial Intelligence uses machine learning [ML], artificial neural network to meet the pharmaceutical science challenges **[3]**. Multi model data combining with healthcare technologies speed up the process of diagnosis and treatment **[4]**. AI covers various methods such as natural language processing, use of robots and computer vision while machine learning includes developing algorithm from the available data of diseases, treatments. The deep learning uses artificial neural network which can learn from data which is available **[5]**. In comparison to traditional ways modern platforms can evaluate millions of compounds with the help of computer-aided drug design [CADD]. This helps to reduce laboratory and material expenses, time **[6]**. High level of complex data and heterogenic data comes from various data resources from pharma companies, text information which is publicly available. New challenges in the pharmaceutical sciences are generated by learning the patterns of biological data **[7]**. Data integration, updated systems, information access to patient are the few technological issues which can be solved by using the AI **[8]**. AI algorithm merging with available data which helps to search new biomarkers can help in early disease detection. Diagnostic biomarkers help to recognize presence of disease. Safety biomarkers recognises the medical product toxicity. This all biomarkers with help of AI

can increase diagnosis process **[9]**. Biomarker driven platforms help to classify patient on basis of characteristics of disease which helps to match the therapies given to patient. Clinical development is reshaped by biomarker guided trial design; biomarkers are utilized in basket trials **[10]**. AI driven tools such as Git-hub Co-pilot, Large language models which can aid in result presentation, code generation. Presently there are two types of ML applications for pharmacodynamics and pharmacokinetics modelling - the only data driven AI algorithm which includes variability, structural models, covariate effects. The second one uses AI algorithm to direct, inform and accelerate creation of non-linear mixed effect model structure **[11]**. The number of suspected adverse effects has increased over period of time as a result of reporting individual case report. To cope with increased workload combining pharmacovigilance with AI is essential. Artificial intelligence driven platforms can also analyse unstructured data, extract text and find patterns in both structured and unstructured narratives **[12]**. The virtual duplicates of an actual physical documents referred to as digital twins. Pharmaceutical digital twins include patient/virtual patient twins used in trial simulation and precision dosing. SmartPharma TwinNet enhance digital twins with AI help **[13][14]**. To improve precision of therapeutic effect AI-based model can make use of medical imaging, clinical records and multi model data. The concept of precision medicines in which patient medication regimen is designed to their unique needs which can be supported combining AI and drug delivery. By using real time monitoring and predictive analysis, AI enabled systems can alter drug release pattern **[15]**. AI driven document processing helps to claim process 80% faster, document accuracy can be increased, also increase the rate of fraud detection, This helps organization to improve compliance, remove insufficiency by using AI which reduces cost and improve customer satisfaction, In order to optimize workflow AI driven document processing combines Optical character recognition [OCR], Machine Learning [ML] increases efficiency by automating classification, conversion of data or documents into digital documents **[16][17]**.

2. FUNDAMENTALS OF AI RELEVANT TO PHARMACEUTICAL SCIENCES

2.1 Machine Learning Models

Supervised Learning: Models are trained here with labelled data. Bioactivity values of molecules to obtain predictive mappings. Supervised learning models include algorithms such as Random forests, support vector machines [SVMs], gradient-boosted trees [XGBoost, LightGBM] and deep neural networks. Toxicity prediction and

QSAR models are mainly based on supervised learning.

Unsupervised Learning: The models discover the hidden patterns in unlabelled data. We explore the chemical space and group patients with autoencoders, dimensionality reduction [PCA, UMAP, t-SNE] and clustering [k-means, DBSCAN] that do not require predefined labels.

Reinforcement Learning: Agents discover the best routes to make decision on the basis of reward signals. RL frameworks like REINVENT used for compounds with desired multi-property in drug design profiles **[18]**.

2.2 Deep Learning Architectures

Deep learning use multi-layered neural networks to extract organised features, which expands on classical machine learning. Convolutional Neural Networks [CNNs], which are the network applied for image-based screening, molecular fingerprint recognition are important architectures in pharmaceutical artificial intelligence. Recurrent Neural Networks and LSTMs: They make the model of the data taken in sequential manner and are used in the analysis of clinical documents and help to create SMILES strings **[19]**.

2.3 Natural Language Processing in Pharma

Natural Language Processing helps extraction of structured data from unstructured data such as biomedical text scientific literature, clinical notes, adverse event reports, and regulatory submissions. Large language models help to improve large structured sets [BioBERT, BioGPT, MedPaLM] which illustrates impressive capabilities in literature searching, drug-drug interaction searching, and clinical documentation assistance **[20]**.

Platform/Tool	Application
Chemprop	Molecular properties prediction
Alpha Fold 2/3	Protein structure prediction
REINVENT	Molecular De novo design
DEEP CHEM	General ML for chemistry

2.4 Key AI Tools and Platforms [21]

3. AI IN DRUG DISCOVERY AND TARGET IDENTIFICATION

3.1 Genomic and Proteomic Target Identification

The most important and complex step in drug development process is to find the suitable biological target and it often fails. To solve this, AI collects different types of biological data and generate graph based networks. Open Target Platforms use Natural Language Processing Models to rank the candidate targets by searching millions of publications, GWAS datasets, gene expression profiles, and

protein interaction networks. Classifiers are trained on features like tissue specificity, evolutionary conservation, and the disease association scores **[22][23]**.

3.2 Protein Structure Prediction: AlphaFold Revolution

The release of AlphaFold2 in 2021 gained a turning point in the field of structural biology and pharmaceutical sciences. More than 200 million protein structure from all known organisms available openly in database due to use of AlphaFold. AlphaFold3 which is released in 2024 increases the possibilities for drug design by increasing predictions of interactions such as protein-ligand, protein-nucleic acid and protein-protein complex **[24]**.

3.3 Virtual Screening and Hit Identification

Traditionally by using high throughput screening [HTS] thousands of compounds are physically tested. By using AI virtual screening chemical libraries are filtered. Atomwise's AtomNet, which is a ground-breaking 3D CNN trained on PDB structures, which shows that it helps to predict binding affinities accurately **[25]**.

4. AI DRIVEN DENOVO MOLECULAR DESIGN AND LEAD OPTIMIZATION

4.1 Generative Molecular Models

Variational Autoencoders [VAEs]: It provide smooth insertion and property-guided optimization by encrypting molecules into continuous latent spaces. In place of flat SMILES strings MITs JTVAE [junction tree VAE] handle its function on the basis of graph.

Transformer-based Generation: SMILES representations such as MolGPT Chemformer build molecular structures which are drug like diverse. This representations train to GPT style models. NVIDIAs MegaMolBART show remarkable generation and retrosynthesis capabilities after being trained on billions of SMILES **[26]**.

4.2 Multi-Property Optimization

Reinforcement learning generates functions that encode multi-parameter optimization [MPO] scores and Pareto-based evolutionary algorithms which when combined with deep learning models become examples of multi-objective optimization frameworks **[27][28]**.

5. AI IN CLINICAL TRIAL DESIGN

5.1 Patient Recruitment

More than 80% of trials face the problem of time bound enrolment and 30% of that fail because of low enrolment. By using various models AI solves this by matching patient populations to trial criteria. Natural Language Processing [NLP] examine unorganized electronic health records [EHRs] **[29]**.

5.2 Adaptive Trial Design

Thousands of possible adaptation events under probable assumption are assisted with

the help of simulation engines and Bayesian statistical frameworks.AI improves adaptive design. ML powered MIPD [Model Informed Precision Dosing] platform can be used for real time pharmacokinetic dosing **[30]**.

5.3 AI-Powered Imaging and Biomarker Analysis

For the analysis of medical images, which can be tumour volume assessment oncology trials, retinal OCT analysis in ophthalmology, MRI in cardiology, deep learning models, mostly CNNs, have shown great performance at or above radiologist level **[31]**.

6. AI IN PHARMACOKINETICS AND ADMET MODELING

6.1 Machine Learning for PK Modelling

In many cases, use of mechanistic compartment models on large scale is done. This are complex and require a previous knowledge, and AI expands these models. ML can be applied to recognize parameters [age, weight, genetic polymorphisms, organ function] which affect drug exposure. ML assisted input parameters are now involved into Simcyp and Gastroplus, which allows PK prediction from preclinical data with much greater accuracy **[32]**.

6.2 ADMET and Toxicity Prediction [33]

ADMET Property	AI Models
Aqueous Solubility	GNN-based model
hERG Cardiotoxicity	DeepHit, CardTox;
Blood-Brain Barrier	Graph-based models integrating P-gp efflux and passive diffusion
Metabolic Stability	Metabolite prediction models [FAME3, SMARTCyp] + half-life regressors

7. AI IN PRECISION MEDICINE AND PHARMACOGENOMICS

7.1 Genomic Biomarker Discovery

AI recognize predictive biomarkers in genomic data. Deep learning models which are applied to tumour RNA sequence profiles assist to identify Gene expression signatures which predict drug response. Computational pathology, which applies convolutional networks to whole slide images [WSI] of tumour biopsies used to recognize genomic mutations **[34]**.

7.2 Drug Repursing

Drug repurposing, which is the process of identifying new indications for already approved drugs. AI approaches for drug repurposing include: network-based methods that build drug-target-disease networks from knowledge graphs and identify repurposing candidates using network proximity metrics; signature-matching that uses transcriptomic profiles [LINCS L1000] to identify drugs that reverse disease gene expression signatures **[35] [36]**.

8. AI IN PHARMACEUTICAL MANUFACTURING AND QUALITY CONTROL

8.1 Process Analytical Technology and Digital Twins

Modern pharmaceutical manufacturing is transformed by AI, Internate of Things [IoT], Industry 4.0. AI for real time monitoring is build up by Process Analytical Technology [PAT] technology which assist in predictive maintenance, batch optimization, and failure mode simulation without interrupting physical production. Machine learning models trained on historical process data [temperature, pressure, humidity, mixing speed] to predict critical quality attributes [CQAs] - particle size, dissolution rate, content uniformity, impurity profiles - in real time. Continuous manufacturing platforms at Pfizer, Eli Lilly, and AstraZeneca utilize ML-based control loops to maintain product quality specifications with minimum human intervention [**37] [38]**.

9. AI IN PHARMACOVIGILANCE

9.1 Adverse Event Signal Detection

Pharmacovigilance is post-market surveillance of adverse drug events [ADEs] that depends on millions of unorganized reports in reporting systems. FDA FAERS, WHO VigiBase, EMA EudraVigilance are the models used for detection of ADEs. Systems powered by NLP pull out structured ADE information from free-text narratives. Deep learning NLP systems [Twitter, Reddit] recognize patient-reported ADEs which are not captured in formal reporting systems **[39]**. Great success achieved on DDI prediction by using models such as knowledge graph implanting models [RotatE, KGNN-LS] and GNN-based frameworks, TWOSIDES, and SIDER and are combined into clinical decision support systems to recognize potentially dangerous drug combinations **[40]**.

10. AI IN INTELLIGENT DRUG DELIVERY SYSTEMS

10.1 Formulation Optimization

Traditional pharmaceutical formulation development is heavily reliant on expert intuition and design of experiments [DoE] to optimize excipient selection, drug-to-excipient ratios, manufacturing processes and release profiles. AI changes this with predictive modelling of formulation-performance relationships. Deep learning models employing physicochemical features of drug-excipient combinations can predict bioavailability, stability, compatibility and dissolution properties **[41]**.

10.2 Targeted Drug Delivery

AI enables the design of stimuli-responsive and actively targeted nanoparticle systems. AI can study single cell RNA sequencing data to find special markers on tumour cells for targeted drug delivery. How nanoparticles spread in the body can be predicted by machine learning models. Nanoparticle properties like surface chemistry, size, ligand amount can be predicted by reinforcement learning to increase targeted drug delivery **[42]**.

11. AI IN REGULATORY SCIENCE AND DRUG APPROVAL

11.1 Regulatory Frameworks

Regulatory agencies have also been active in the development of AI in pharmaceuticals. The FDA's 2021 guidelines for Artificial Intelligence/Machine Learning [AI/ML] Based Software as a Medical Device [SaMD] and draft guidance for 2023 on AI/ML in drug development describe requirements for the validation, monitoring, and transparency of AI tools used in regulatory submissions **[43]**.

11.2 Document Processing and Review Acceleration

Regulatory submissions for new drug applications [NDAs] are often made up of thousands of pages of clinical, nonclinical data and these can be analysed automatically by AI-powered document analysis tools to extract relevant information, identify inconsistencies, flag missing data packages and suggest relevant precedent rulings from prior submissions that can help speed up the preparation of submissions and regulatory review **[44]**.

12. CHALLENGES, ETHICAL CONSIDERATIONS

12.1 Data Quality and Representativeness

The quality, completeness, and representativeness of the training data are key limitations of AI models. Major systematic biases in pharmaceutical databases include over-representation of some chemical scaffolds [Lipinski-compliant oral drugs], under-representation of some disease areas and populations. Models trained on such data are susceptible to inheriting these biases and making predictions that may not generalize to new chemical series or under-represented patient populations **[45] [46]**.

12.2 Regulatory Uncertainty and Validation

Regulatory bodies demand accurate prospective validation to illustrate the fitness for purpose of AI models. ML validation metrics [cross-validation AUROC, RMSE] may not adequately show prospective real-world performance. Challenges are created for pharmaceutical companies to use AI in regulatory submission due to variation in regulations across different countries **[47]**.

12.3 Ethical Dimensions

For fair use of AI in pharmaceutical sciences, it is important to test AI performance on different population groups. Privacy should be maintained during the process. Federated learning is the AI method which maintains privacy. In this method models are trained on basis of data from different hospitals without sharing sensitive patient information **[48]**.

13. FUTURE PERSPECTIVES

Foundation Models for Drug Discovery: For the purpose of pharmaceutical research large AI models are trained on huge datasets

of molecules, proteins and clinical information. These involves models like ESM-3, Evo, Openfold can help for specific drug development task.

Quantum-AI Convergence: Scientist take help of quantum computing to simulate molecular behaviour and this helps to improve drug design. Early studies also combine quantum computing with AI models such as quantum graph neural networks **[49]**.

14. CONCLUSION

Artificial intelligence represents the greatest technological revolution currently revolutionizing the field of pharmaceutical sciences. From computational target discovery to drug design, clinical trial management, quality control during production, pharmacovigilance, and precision medicine, AI systems have already shown their utility by delivering tangible benefits in terms of shortened timelines, decreased attrition rates, minimized costs, and increased safety. With the combination of AI technologies with rapidly expanding biological databases, increasing computational power, and sophisticated machine learning algorithms, the revolution is being accelerated. Nevertheless, overcoming numerous obstacles remains a key prerequisite to achieving wide-ranging implementation of AI within the pharmaceutical industry. The future pharmacist is one who is AI-savvy and has knowledge not only of the biological and chemical principles behind drug discovery but also of the computational tools that have become indispensable in the field.

REFERENCES

[1] Vora LK, Gholap AD, Jetha K, Thakur RRS, Solanki HK, Chavda VP. Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. Pharmaceutics. 2023 Jul 10;15[7]:1916. doi:10.3390/pharmaceutics15071916 PubMed PMID: 37514102; PubMed Central PMCID: PMC10385763.

[2] Kant S, Deepika, Roy S. Artificial intelligence in drug discovery and development: transforming challenges into opportunities. Discov Pharm Sci. 2025 Jun 2;1[1]:7. doi:10.1007/s44395-025-00007-3

[3] Fu C, Chen Q. The future of pharmaceuticals: Artificial intelligence in drug discovery and development. J Pharm Anal. 2025 Feb 1;15:101248. doi:10.1016/j.jpha.2025.101248

[4] Bajwa J, Munir U, Nori A, Williams B. Artificial intelligence in healthcare: transforming the practice of medicine. Future Healthc J. 2021 Jul;8[2]:e188–94. doi:10.7861/fhj.2021-0095 PubMed

PMID: 34286183; PubMed Central PMCID: PMC8285156.

[5] Huanbutta K, Burapapadh K, Kraisit P, Sriamornsak P, Ganokratanaa T, Suwanpitak K, *et al*. Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance. Eur J Pharm Sci. 2024 Dec 1;203:106938. doi:10.1016/j.ejps.2024.106938

[6] Farr N. AI in drug development. Pivotal CRO [Internet]. 2026 Mar 2 [cited 2026 May 3]. Available from: https://pivotalcr.com/ai-in-drug-development-a-cros-strategic-roadmap/

[7] Lu M, Yin J, Zhu Q, Lin G, Mou M, Liu F, *et al*. Artificial Intelligence in Pharmaceutical Sciences. Engineering. 2023 Aug 1;27:37–69. doi:10.1016/j.eng.2023.01.014

[8] admin. Artificial Intelligence: A Future of Pharmaceutical Industries. International Journal Of Pharmaceutical Sciences And Research [Internet]. 2025 Jul 31 [cited 2026 May 3]. Available from: https://ijpsr.com/bft-article/artificial-intelligence-a-future-of-pharmaceutical-industries/

[9] Javaid H, Petrescu CC, Schmunk LJ, Monahan JM, O'Reilly P, Garg M, *et al*. The impact of artificial intelligence on biomarker discovery. Emerg Top Life Sci. 2025 Sep 9;8[2]:89. doi:10.1042/ETLS20243003 PubMed PMID: 40924944.

[10] Raedt SD. Drug Target Review [Internet]. [cited 2026 May 3]. AI and the future of biomarker analysis in early R&D. Available from:https://www.drugtargetreview.com/ai-and-the-future-of-biomarker-analysis-in-early-randd/680428.article

[11] Huang Z, Denti P, Mistry H, Kloprogge F. Machine Learning and Artificial Intelligence in PK-PD Modeling: Fad, Friend, or Foe? Clin Pharmacol Ther. 2024 Jan 5;115[4]:652–4. doi:10.1002/cpt.3165 PubMed PMID: 38179832; PubMed Central PMCID: PMC11146679.

[12] Desai MK. Artificial intelligence in pharmacovigilance – Opportunities and challenges. Perspect Clin Res. 2024;15[3]:116–21. doi:10.4103/picr.picr_290_23 PubMed PMID: 39140015; PubMed Central PMCID: PMC11318788.

[13] Rahman P, Mehnaz S. International Journal for Multidisciplinary Research [IJFMR]. SSRN Electron J. 2024. doi:10.2139/ssrn.5054029

[14] Huang W, Wang X, Chen Y, Yu C, Zhang S. Advancing drug-drug interactions research: integrating AI-powered prediction, vulnerable populations, and regulatory insights. Front Pharmacol. 2025 Aug 13;16:1618701. doi:10.3389/fphar.2025.1618701 PubMed PMID: 40880653; PubMed Central PMCID: PMC12380558.

[15] Khawaji M. Integrating Artificial Intelligence For Targeted Drug Delivery And Therapeutic Optimization.

[16] AI-driven intelligent document processing for healthcare and insurance. ResearchGate. doi:10.30574/ijsra.2025.14.1.0194

[17] Ajisafe OM, Adekunle YA, Egbon E, Ogbonna CE, Olawade DB. The role of machine learning in predictive toxicology: A review of current trends and future perspectives. Life Sci. 2025 Oct 1;378:123821. doi:10.1016/j.lfs.2025.123821

[18] Obaido G, Mienye ID, Egbelowo OF, Emmanuel ID, Ogunleye A, Ogbuokiri B, *et al*. Supervised machine learning in drug discovery and development: Algorithms, applications, challenges, and prospects. Mach Learn Appl. 2024 Sep 1;17:100576. doi:10.1016/j.mlwa.2024.100576

[19] Javid S, Rahmanulla A, Ahmed MG, sultana R, Prashantha Kumar BR. Machine learning & deep learning tools in pharmaceutical sciences: A comprehensive review. Intell Pharm. 2025 Jun 1;3[3]:167–80. doi:10.1016/j.ipha.2024.11.003

[20] Trajanov D, Trajkovski V, Dimitrieva M, Dobreva J, Jovanovik M, Klemen M, *et al*. Review of Natural Language Processing in Pharmacology. Pharmacol Rev. 2023 Jul 1;75[4]:714–38. doi:10.1124/pharmrev.122.000715

[21] Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021 Jan;26[1]:80–93. doi:10.1016/j.drudis.2020.10.010 PubMed PMID: 33099022; PubMed Central PMCID: PMC7577280.

[22] Arora L, Akhare Y, Latha YLM, Road N, Das SK. Bioinformatics Applications of Artificial

Intelligence in Genomics and Proteomics.

[23] Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, *et al*. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. The Lancet. 2020 Feb 15;395[10223]:e30–1. doi:10.1016/S0140-6736[20]30304-4 PubMed PMID: 32032529.

[24] Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, *et al*. Highly accurate protein structure prediction with AlphaFold. Nature. 2021 Aug;596[7873]:583–9. doi:10.1038/s41586-021-03819-2

[25] Bharadwaj S, Deepika K, Kumar A, Jaiswal S, Miglani S, Singh D, *et al*. Exploring the Artificial Intelligence and Its Impact in Pharmaceutical Sciences: Insights Toward the Horizons Where Technology Meets Tradition. Chem Biol Drug Des. 2024;104[4]:e14639. doi:10.1111/cbdd.14639

[26] Méndez-Lucio O, Baillif B, Clevert DA, Rouquié D, Wichard J. De novo generation of hit-like molecules from gene expression signatures using artificial intelligence. Nat Commun. 2020 Jan 3;11[1]:10. doi:10.1038/s41467-019-13807-w

[27] Luukkonen S, van den Maagdenberg HW, Emmerich MTM, van Westen GJP. Artificial intelligence in multi-objective drug design. Curr Opin Struct Biol. 2023 Apr 1;79:102537. doi:10.1016/j.sbi.2023.102537

[28] Zhavoronkov A, Vanhaelen Q, Oprea TI. Will Artificial Intelligence for Drug Discovery Impact Clinical Pharmacology? Clin Pharmacol Ther. 2020;107[4]:780–5. doi:10.1002/cpt.1795

[29] [PDF] AI-Driven Patient Recruitment Strategies for Healthcare Clinical Trials Journal of Artificial Intelligence, Machine Learning and Data Science [Internet]. [cited 2026 May 4]. Available from: https://www.researchgate.net/publication/397872969_AI-Driven_Patient_Recruitment_Strategies_for_Healthcare_Clinical_Trials_Journal_of_Artificial_Intelligence_Machine_Learning_and_Data_Science?utm_source=chatgpt.com

[30] Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, *et al*.

Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med. 2018 Feb 28;16[1]:29. doi:10.1186/s12916-018-1017-7

[31] Rajpurkar P, Irvin J, Zhu K, Yang B, Mehta H, Duan T, *et al*. CheXNet: Radiologist-Level Pneumonia Detection on Chest X-Rays with Deep Learning. 2017 Nov 14. doi:10.48550/arXiv.1711.05225

[32] Varela-Rey I, Bandín-Vilar E, Toja-Camba FJ, Cañizo-Outeiriño A, Cajade-Pascual F, Ortega-Hortas M, *et al*. Artificial Intelligence and Machine Learning Applications to Pharmacokinetic Modeling and Dose Prediction of Antibiotics: A Scoping Review. Antibiotics. 2024 Dec;13[12]:1203. doi:10.3390/antibiotics13121203

[33] M M, S M, Kate SS, Taneja I, Jaiswal S, Pratap B, *et al*. A review on integrated machine learning and deep learning driven artificial intelligence models for pharmacokinetics and toxicokinetics predictions, and their application. Drug Metab Dispos. 2026 Mar 1;54[3]:100240. doi:10.1016/j.dmd.2026.100240

[34] Tran KA, Kondrashova O, Bradley A, Williams ED, Pearson JV, Waddell N. Deep learning in cancer diagnosis, prognosis and treatment selection. Genome Med. 2021 Sep 27;13[1]:152. doi:10.1186/s13073-021-00968-x

[35] Zhu Y, Che C, Jin B, Zhang N, Su C, Wang F. Knowledge-driven drug repurposing using a comprehensive drug knowledge graph. Health Informatics J. 2020 Dec 1;26[4]:2737–50. doi:10.1177/1460458220937101

[36] Topriceanu CC, Chaturvedi N, Mathur R, Garfield V. Validity of European-centric cardiometabolic polygenic scores in multi-ancestry populations. Eur J Hum Genet. 2024 Jun;32[6]:697–707. doi:10.1038/s41431-023-01517-3

[37] Arden NS, Fisher AC, Tyner K, Yu LX, Lee SL, Kopcha M. Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future. Int J Pharm. 2021 Jun 1;602:120554. doi:10.1016/j.ijpharm.2021.120554

[38] El-Dahiyat F, Fahelelbom KMS, Jairoun AA, Al-Hemyari SS. Combatting Substandard and Falsified Medicines: Public Awareness and Identification of

Counterfeit Medications. Front Public Health. 2021 Oct 26;9:754279. doi:10.3389/fpubh.2021.754279 PubMed PMID: 34765583; PubMed Central PMCID: PMC8575769.

[39] Pilipiec P, Liwicki M, Bota A. Using Machine Learning for Pharmacovigilance: A Systematic Review. Pharmaceutics. 2022 Feb;14[2]:266. doi:10.3390/pharmaceutics14020266

[40] Besharatifard M, Vafaee F. A review on graph neural networks for predicting synergistic drug combinations. Artif Intell Rev. 2024 Feb 13;57[3]:49. doi:10.1007/s10462-023-10669-z

[41] Wang S, Di J, Wang D, Dai X, Hua Y, Gao X, *et al*. State-of-the-Art Review of Artificial Neural Networks to Predict, Characterize and Optimize Pharmaceutical Formulation. Pharmaceutics. 2022 Jan;14[1]:183. doi:10.3390/pharmaceutics14010183

[42] Singh S, De A. The paradigm shift in therapeutics: a comprehensive review of artificial intelligence in drug delivery systems. RSC Pharm. 2026. doi:10.1039/D5PM00235D

[43] Research C for DE and. FDA [Internet]. FDA; 2026 [cited 2026 May 4]. Artificial Intelligence for Drug Development. Available from: https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/artificial-intelligence-drug-development

[44] Huanbutta K, Burapapadh K, Kraisit P, Sriamornsak P, Ganokratanaa T, Suwanpitak K, *et al*. Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance. Eur J Pharm Sci. 2024 Dec 1;203:106938. doi:10.1016/j.ejps.2024.106938

[45] Artificial Intelligence in Small-Molecule Drug Discovery: A Critical Review of Methods, Applications, and Real-World Outcomes [Internet]. [cited 2026 May 4]. Available from: https://www.mdpi.com/1424-8247/18/9/1271?utm_source=chatgpt.com

[46] Qadri YA, Shaikh S, Ahmad K, Choi I, Kim SW, Vasilakos AV. Explainable Artificial Intelligence: A Perspective on Drug Discovery. Pharmaceutics. 2025

Sep;17[9]:1119. doi:10.3390/pharmaceutics17091119

[47] Mirakhori F, Niazi SK. Harnessing the AI/ML in Drug and Biological Products Discovery and Development: The Regulatory Perspective. Pharmaceuticals. 2025 Jan;18[1]:47. doi:10.3390/ph18010047

[48] Ueda D, Kakinuma T, Fujita S, Kamagata K, Fushimi Y, Ito R, *et al*. Fairness of artificial intelligence in healthcare: review and recommendations. Jpn J Radiol. 2024 Jan 1;42[1]:3–15. doi:10.1007/s11604-023-01474-3

[49] Aritra S, Shikha CB, Indu S. Harnessing the power of artificial intelligence in pharmaceuticals: Current trends and future prospects. Intell Pharm. 2025 Jun 1;3[3]:181–92. doi:10.1016/j.ipha.2024.12.001